Metis Techbio-p
7666.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.23B
Close$
$-0.70
105.9% downside
Current Fair Value
105.9% downsideOvervalued by 105.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.23 Billion |
|---|---|
| Enterprise Value | $17.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 2.15 |
| Outstanding Shares | 1,182,697,850 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -40.19 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$492,075
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Metis Techbio-p
150 employees
CEO: Tsai-Ta Lai Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's...